Plato Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Plato Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.65M	Hold	5,935	–	–	0.18%	130
2025 Q4	$2.7M	Sell	5,935 -91	-2%	-$39.2K	0.18%	123
2025 Q3	$2.34M	Buy	6,026 +197	+3%	+$82.3K	0.16%	135
2025 Q2	$2.59M	Buy	5,829 +4	+0.1%	+$1.84K	0.19%	113
2025 Q1	$2.85M	Sell	5,825 -820	-12%	-$382K	0.24%	97
2024 Q4	$2.69M	Hold	6,645	–	–	0.2%	114
2024 Q3	$3.09M	Hold	6,645	–	–	0.25%	100
2024 Q2	$3.11M	Buy	6,645 +505	+8%	+$219K	0.29%	82
2024 Q1	$2.57M	Buy	6,140 +5,350	+677%	+$2.26M	0.27%	99
2023 Q4	$321K	Buy	+790	New	+$292K	0.39%	61

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Plato Investment Management's VRTX Position: Q1 2026 in Review

Plato Investment Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 5,935 shares worth $2.65M. The position accounts for 0.18% of the portfolio, ranked #130.

Plato Investment Management first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $3.11M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Plato Investment Management held 5,935 shares of Vertex Pharmaceuticals worth $2.65M as of Q1 2026.
Plato Investment Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.18% of Plato Investment Management's portfolio in Q1 2026, its #130 holding.
Plato Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Plato Investment Management's Vertex Pharmaceuticals position peaked at $3.11M in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Plato Investment Management's 13F filing for Q1 2026, filed 5 May 2026.